ASCO Education

Dr. James Harding (Memorial Sloan Kettering) is a board-certified medical oncologist specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. In this week's episode, he discusses a new checkpoint inhibitor with monoclonal antibodies to programmed death receptor 1 (PD-1) for patients with Hepatocellular Carcinoma (HCC). He presents a clinical case and to highlight several aspects of immunotherapy for liver cancer.

Dr. Amy Comander, a hematologist-oncologist specializing in breast cancer at Mass General Hospital, and Dr. Rachel Jimenez, Associate Program Director of Harvard Radiation Oncology Residency Program, have a personal discussion about burnout and practical ways to combat it.

Dr. Karen Autio, a medical specializing in the treatment of prostate cancer at Memorial Sloan Kettering Cancer Center in New York, discusses additional treatments beyond Anti-PD-1/PD-L1 therapy.

In this episode of ASCO eLearning Weekly Podcast Dr. Alessandro Fichera, Division Chief of Gastrointestinal Surgery at University of North Carolina at Chapel Hill, discusses clinical choices in managing rectal cancer. When is surgery the correct choice? When can we put down the knife?

Rona D. Yaeger, MD is a Medical Oncologist at Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY. In this special Annual Meeting 2019 episode, she discusses recent biomarker and targeted therapy treatments for colorectal cancer management.

Dr. Tarita Thomas is a radiation oncologist in Chicago, Illinois. She received her medical degree from Northwestern University Feinberg School of Medicine and has been in practice between 6-10 years. In this episode, Dr. Thomas discusses the role of adjuvant radiotherapy in nodal disease. The ASCO eLearning Weekly Podcast is an educational series focused on helping learners identify knowledge gaps and stay up-to-date with the latest in new drug developments, cancer treatments and patient care approaches. If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO eLearning. Subscribe to the podcast through a mobile device by clicking the Apple Podcasts link (iOS devices) or the Google Play Music link (Android devices). We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO eLearning Weekly Podcast, email elearning@asco.org for more information.

Dr. Daniel George is Professor of Medicine and Surgery, Director of GU Oncology for the Duke Cancer Institute, and Co-Chair of the DCI Center for Prostate and Urologic Cancers. Dr George's primary areas of interest are in drug development and optimizing care for patients with GU cancers, particularly prostate and kidney cancers. In this episode, Dr. George reviews disparities in prostate care. The ASCO eLearning Weekly Podcast is an educational series focused on helping learners identify knowledge gaps and stay up-to-date with the latest in new drug developments, cancer treatments and patient care approaches. If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO eLearning. Subscribe to the podcast through a mobile device by clicking the Apple Podcasts link (iOS devices) or the Google Play Music link (Android devices). We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO eLearning Weekly Podcast, email elearning@asco.org for more information.

Alexander Menzies, a Medical Oncologist and Associate Professor of Melanoma Medical Oncology at Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals discusses appropriate biomarkers and treatments for Stage IV Melanoma.

Lora Black, RN, MPH, OCN, CCRP, Senior Director of Clinical Research at Sanford Health highlights two key points for building a sustainable oncology research program in an oncology-based setting.